Lausanne, Switzerland – June 22, 2017 – Debiopharm Investment (Debiopharm – www.debiopharm.com ), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced the sale of 100% of Aloe Energy from a consortium including Aloem, Ardian Infrastructure and Debiopharm Investment to Sonnedix.
Sonnedix strengthens its presence in France through the acquisition of Aloe Energy, a successful Solar PV developer and operator with 67MW in operation as well as a pipeline of projects under development and construction together with a team of skilled developers and operators. This is the fifth significant acquisition Sonnedix has completed in the last eighteen months, totalling more than 300MW of operating projects with a total asset value of more than €1.4bn.
These acquisitions have more than doubled Sonnedix’s solar capacity in construction and operation, now exceeding 600MW, with an overall portfolio over 1.2GW globally. Sonnedix now ranks as France’s 4th largest solar player, controlling 155MW of operating PV plants across France, in addition to more than 100MW in each of Italy and Spain.
“We are excited about the further integration in France and delighted to welcome the Aloe Energy team to Sonnedix, which has just in the last auction demonstrated the strength of their project development capabilities – we look forward to working together to continue our growth in France and across Europe”, said Andreas Mustad, Sonnedix’s CEO.
Sonnedix acquired Aloe Energy from a consortium including Aloem, Ardian Infrastructure and Debiopharm Investment. Sonnedix was advised by Astris Finance (financial), Linklaters (legal), OST (technical) and EY (accounting / tax).
The Sellers were advised by Gide (legal/tax/structure), Société Générale (financial modeling), G-advisory (technical), PwC (accounting), Arsene Taxand (tax) and PGA (legal).
Sonnedix Power Holdings Limited (together with its subsidiaries, “Sonnedix”), is an Independent Solar Power Producer (IPP) with a proven track record in delivering high performance cost competitive solar photovoltaic plants to the market. Sonnedix develops, builds, owns and operates solar power plants globally.
For more information about Sonnedix, please visit www.sonnedix.com
For further information please contact Hamir Patel on +44 7771 780 946 or email@example.com
Aloem is a private equity investment vehicle focused on long term sustainable businesses, managed by Jean-Pascal Tranie – the President of Aloe Invest through Aloe Private Equity until the Transaction – and a team composed notably of Laura Develter and Luc-Emmanuel Barreau.
Ardian, founded in 1996 and led by Dominique Senequier, is an independent private investment company with assets of US$62bn managed or advised in Europe, North America and Asia. The company, which is majority- owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty and entrepreneurship. Ardian maintains a truly global network, with more than 450 employees working through twelve offices in Paris, London, Frankfurt, Milan, Madrid, Zurich, New York, San Francisco, Beijing, Singapore, Jersey, Luxembourg. The company offers its 580 investors a diversified choice of funds covering the full range of asset classes, including Ardian Funds of Funds (primary, early secondary and secondary), Ardian Private Debt, Ardian Buyout (including Ardian Mid Cap Buyout Europe & North America, Ardian Expansion, Ardian Growth and Ardian Co-Investment), Ardian Infrastructure, Ardian Real Estate and Ardian Mandates.
Further information on: www.ardian.com
About Debiopharm Investment SA
Debiopharm Investment SA pursues its mission to preserve, diversify and support the sustainable growth of Debiopharm Group™, a biopharmaceutical development company based in Lausanne (Switzerland), through a comprehensive investment strategy centered on three areas of activity: Finance (portfolio management, currency hedging), Real Estate (residential and commercial) and Private Equity.
The Private Equity team focuses primarily on investment diversification, managing a portfolio of funds and of direct equity investments, as minority shareholder, in the capital of pioneering start-ups as well as small and medium-sized European companies.
Our entrepreneurial culture, as well as our willingness and capacity to act as long-term partners of the teams with which we invest, are the established pillars of our commitment.
For more information, please visit www.debiopharm.com